Dr. Michael A. Postow
Claim this profileMemorial Sloan Kettering Cancer Center
Area of expertise
Melanoma
Michael A. Postow has run 6 trials for Melanoma. Some of their research focus areas include:
Skin Cancer
Michael A. Postow has run 2 trials for Skin Cancer. Some of their research focus areas include:
Affiliated Hospitals
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Bergen
Clinical Trials Michael A. Postow is currently running
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting
1 award
Phase 2 & 3
23 criteria
Biomarker-Guided Immunotherapy Discontinuation
for Melanoma
This trial uses drugs that boost the immune system to fight advanced melanoma that can't be surgically removed. It aims to see if doctors can safely shorten the treatment period by using imaging tests to guide decisions. Pembrolizumab and ipilimumab are immunotherapy drugs used to treat advanced melanoma, with pembrolizumab approved for younger patients and ipilimumab showing positive results in previous studies.
Recruiting
1 award
Phase 2
22 criteria
More about Michael A. Postow
Clinical Trial Related
10 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Michael A. Postow has experience with
- Ipilimumab
- Nivolumab
- Ipilimumab And Nivolumab Combination Immunotherapy
- PET Scan
- Surgical Resection Of Melanoma
- Dabrafenib
Breakdown of trials Michael A. Postow has run
Melanoma
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael A. Postow specialize in?
Michael A. Postow focuses on Melanoma and Skin Cancer. In particular, much of their work with Melanoma has involved Stage IV patients, or patients who are Stage III.
Is Michael A. Postow currently recruiting for clinical trials?
Yes, Michael A. Postow is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Michael A. Postow has studied deeply?
Yes, Michael A. Postow has studied treatments such as Ipilimumab, Nivolumab, Ipilimumab and Nivolumab Combination Immunotherapy.
What is the best way to schedule an appointment with Michael A. Postow?
Apply for one of the trials that Michael A. Postow is conducting.
What is the office address of Michael A. Postow?
The office of Michael A. Postow is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.